Compare AMCR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCR | NBIX |
|---|---|---|
| Founded | 1926 | 1992 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 14.4B |
| IPO Year | N/A | 1996 |
| Metric | AMCR | NBIX |
|---|---|---|
| Price | $8.31 | $155.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $10.40 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 22.7M | 969.9K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | 0.32 | ★ 4.19 |
| Revenue | ★ $17,401,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $57.16 | $23.76 |
| Revenue Next Year | $1.28 | $18.01 |
| P/E Ratio | ★ $25.88 | $37.10 |
| Revenue Growth | ★ 28.42 | 19.61 |
| 52 Week Low | $7.67 | $84.23 |
| 52 Week High | $10.47 | $157.67 |
| Indicator | AMCR | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 64.81 |
| Support Level | $8.31 | $150.26 |
| Resistance Level | $8.59 | $154.35 |
| Average True Range (ATR) | 0.14 | 4.16 |
| MACD | -0.03 | 1.07 |
| Stochastic Oscillator | 11.39 | 93.25 |
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.